RYVU Therapeutics S.A. — Capital/Financing Update 2024

Jan 17, 2024

Take-up of series K subscription warrants by the European Investment Bank

The Management Board of Ryvu Therapeutics S.A. with its registeredoffice in Krakow (the "Company"), with reference to current report no.14/2022 of 17 August 2022, no. 19/2023 of 5 May 2023 and no. 33/2023 of19 June 2023, hereby informs that on January 17, 2024 the Companyentered into an agreement with the European Investment Bank with itsseat in Luxembourg (_quot;EIB_quot;) for the subscription of series K subscriptionwarrants (_quot;Warrants_quot;), under which the EIB subscribed for 592,825 (fivehundred and ninety-two thousand eight hundred and twenty-five) Warrants,each of which entitles to subscribe for one series K share of theCompany. The Warrants were taken up by the EIB free of charge.

Disclaimer: This English language translation has been prepared solelyfor the convenience of English-speaking readers. Despite all the effortsdevoted to this translation, certain discrepancies, omissions orapproximations may exist. In case of any differences between the Polishand the English versions, the Polish version shall prevail. RyvuTherapeutics S.A., its representatives and employees decline allresponsibility in this regard.